NICE recommendation for Rhythm’s Imcivree

Rhythm Pharmaceuticals (Nasdaq: RYTM), a US biopharma specializing in rare neuroendocrine diseases, has announced that its drug Imcivree (setmelanotide) is expected to be funded and available for use in England and Wales within three months through the National Health Service (NHS) in specialist centers.

The National Institute for Health and Care Excellence (NICE) has issued guidance that recommends Imcivree as an option for treating obesity and the control of hunger (hyperphagia) in genetically confirmed Bardet-Biedl syndrome (BBS) in people six years of age and over.

This recommendation applies if patients are between six and 17 years of age when treatment starts. Patients may remain on reimbursed Imcivree as adults while they continue to benefit from therapy.